ClinicalTrials.gg
Not yet recruitingNCT06719908Updated Dec 6, 2024

A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers

A Phase 1 interventional study of AFA-281 is a small molecule, orally available and Alcohol (Ethanol) in Alcohol and Alcohol Use Disorders, sponsored by Afasci Inc. Not yet recruiting. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Afasci Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate if alcohol interacts with the drug candidate AFA-281 in adults (healthy volunteers). This trial will evaluate blood concentration levels of AFA-281 and ethanol. The main questions it aims to answer are: Does alcohol interact with AFA-281? What are the side effects (if any)? Researchers will compare AFA-281 to a placebo (a look-alike substance that contains no drug) to see if AFA-281 interacts with alcohol.

Participants will take a total of 4 treatment sessions separated by at least 2 days between treatments. The treatments will incorporate AFA-281 or placebo with ethanol or ethanol placebo. After each treatment vital signs will be monitored and blood collected to measure AFA-281 and ethanol levels. Participants will provide an assessment survey of symptoms. The total treatment time will be 9 inpatient days (8 nights), and a final follow-up visit 3 to 5 days after clinic discharge.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, 4-way crossover study of the interaction of alcohol and oral AFA-281 in healthy adult volunteers. This study will evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) effects of co-administration of AFA-281 and ethanol in healthy, male and female subjects who are social or moderate drinkers but do not meet criteria for the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of Alcohol Use Disorder. Each subject will receive single doses of AFA-281, ethanol, placebo for AFA-481, and placebo for ethanol in a randomized, double-blind, crossover manner. Randomized blocks will be included to ensure that there is 1 day in between treatment sessions. Blood will be collected for PK and blood alcohol levels at pre-dose and at multiple timepoints after treatment. Safety parameters will be evaluated for tolerability such as vital signs and clinical pathology. Participants will provide an assessment survey of symptoms. The total treatment time will be 9 inpatient days (8 nights), and a final follow-up visit 3 to 5 days after clinic discharge.

02

Conditions studied

  • Alcohol
  • Alcohol Use Disorders

Browse trials for

Keywords

  • AFA-281
  • Alcohol
  • Ethanol
  • Healthy Volunteer
03

In context

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

This study's planned enrollment of 20 is below the median of 88 across 1,430 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

Afasci Inc is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between 21 and 55 years of age, inclusive.
  • Must voluntarily sign and date each , approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.
  • Currently consumes alcohol regularly (defined as having consumed 7 to 21 standard drinks per week on average in the 6 months prior to screening and having consumed ≥5 standard drinks on at least one occasion in the 30 days prior to screening) but does not meet the criteria for Alcohol Use Disorder. Note: one standard alcoholic drink is equivalent to 1.5 oz. hard liquor or 5 oz. wine or 12 oz. beer.
  • (BMI) within the range of 18.5 to 30.0 kg/m2, inclusive.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead (ECG) at the screening visit
  • Adequate venous access
  • Must be surgically sterile (vasectomy, tubal ligation or hysterectomy) or agree to be sexually inactive or agree to use a barrier method of (i.e., condom) from the start of screening until study completion, and agree to refrain from donating sperm, for 90 days after study drug administration.
  • Agree to abstain from strenuous exercise during the inpatient stay of the study.

Exclusion criteria

Exclusion Criteria:

  • History of significant sensitivity to any drug.
  • Has a abnormal or an ECG with a corrected for heart rate using the Fridericia formula (QTcF) > 430 msec.
  • Has an estimated (CrCl) outside of normal range.
  • History of head trauma with loss of consciousness, seizures or convulsions, including febrile, alcohol or drug withdrawal seizures.
  • History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.
  • Requirement for any over-the-counter and/or prescription medication, vitamins and/or herbal supplements on a regular basis.
  • Use of any medications, vitamins and/or herbal supplements within the 2-week period prior to study drug administration.
  • Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), surface antigen (HBsAg) or virus antibody (HCV Ab) or antibodies (HIV Ab). Negative HIV status will be confirmed at Screening and the results will be maintained confidentially by the study site.
  • Display any latent signs of alcohol withdrawal per the Clinical Institute Withdrawal of Alcohol Assessment-Revised (CIWA-AR).
  • History or current diagnosis of a substance use disorder.
  • Positive urine drug screen for drugs of abuse at Screening or Day -1.
  • Consumption of alcohol within the 1-day period prior to study drug administration.
  • Receipt of any drug by injection within 30 days prior to study drug administration.
  • History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, endocrine, dermatological, metabolic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • A clinically notable vital sign abnormality including a history of syncopal or near syncopal events following abrupt change in posture.
  • History of cardiac disease, including family history of long-QT syndrome, second degree heart block Type II, third degree heart block or unexplained sudden deaths in their family.
  • Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration.
  • Pregnant or nursing women
  • Receipt of any product within 6 weeks prior to study drug administration.
  • Consumption of grapefruit or grapefruit products from 3 days prior to study drug administration.
  • Use of tobacco or nicotine-containing products within the 6-month period preceding study drug administration.
  • Current enrollment in another clinical study.
  • Previous enrollment in this study.
  • Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive AFA-281.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    AFA-281 with Ethanol

    AFA-281 (40 mg) will be administered as a single dose (oral) in combination with Alcohol (0.6 g/kg in females or 0.7g/kg in males).

    Drug: AFA-281 is a small molecule, orally available · Other: Alcohol (Ethanol)

  • Placebo comparator
    AFA-281 with Ethanol Placebo

    AFA-281 (40 mg) will be administered as a single dose (oral) in combination with the Alcohol placebo (0.6 g/kg in females or 0.7g/kg in males).

    Drug: AFA-281 is a small molecule, orally available

  • Placebo comparator
    AFA-281 placebo with Ethanol

    AFA-281 placebo (40 mg) will be administered as a single dose (oral) in combination with the Alcohol (0.6 g/kg in females or 0.7g/kg in males).

    Other: Alcohol (Ethanol)

  • Sham comparator
    AFA-281 placebo with Ethanol placebo

    AFA-281 placebo (40 mg) will be administered as a single dose (oral) in combination with the Alcohol placebo (0.6 g/kg in females or 0.7g/kg in males).

    Drug: AFA-281 is a small molecule, orally available · Other: Alcohol (Ethanol)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic evaluation of AFA-281

    Evaluation of AFA-281 concentrations in the blood over time

    Time frame: Predose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 4, 5, 6, 7, 8, 12 and 24 hours post dose

  2. Evaluation of ethanol levels in the blood

    Measure ethanol concentrations in the blood over time

    Time frame: Collected at 2, 2.25, 2.5, 2.75, 3, 3.25, 4, 5, 6, 7, 8, 12 and 24 hours post administration

  3. Dizziness visual analog scale (VAS) assessment

    Central nervous system test. Visual Analogue Scale for dizziness assessment on a scale 0 to 10. 0 no dizziness and 10 worst

    Time frame: Collected at predose, 1, 2, 3, 4, 6 and 8 hours post dose

  4. Choice Reaction Time (CRT) evaluation

    Central nervous system test. The subject is required to respond to one stimulus, the quicker the better

    Time frame: Predose and 1, 2, 3, 4, 6 and 8 hours post dose

  5. Balance Platform assessment

    Central nervous system test. Balance platform assessment

    Time frame: Predose and 1, 2, 3, 4, 6 and 8 hours post dose

  6. Match to Sample Visual Search (MTS) assessments

    Central nervous system test. Assesses attention and visual searching, with a speed accuracy trade-off. The quicker, the better.

    Time frame: 1, 2, 4 and 8 hours post dose

  7. Alertness visual analog scale (AVAS)

    Central nervous system test. Asks a subject to indicate their feelings on a line with a scale from 0 mm on the left to 100 mm on the right. The scale can be used to assess sleepiness and other subjective experiences.

    Time frame: 1, 2, 4 and 8 hours post dose

Secondary outcomes

  1. Clinical chemistry

    Blood test for metabolic panel

    Time frame: Baseline, pre-intervention and in 24 hours after completion of the intervention

  2. A complete blood count (CBC) with differential

    complete blood count with differential

    Time frame: Baseline, pre-intervention and in 24 hours after completion of the intervention

  3. Heart Rate

    Measurement of heart rate

    Time frame: Predose, 1, 2, 4 hours post dose

  4. Blood pressure, both systolic, and diastolic pressure

    Measurement of blood pressure

    Time frame: Predose, 1, 2, 4 hours post dose

  5. Body weight

    Measurement of body weight

    Time frame: Baseline, pre-intervention and after in 24 hours of the intervention

  6. Electrocardiogram (ECG) including P Wave, QRS Complex, and QT Interval, etc.)

    ECG assessment

    Time frame: Baseline, pre-intervention and 2 hours post dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jul 2026, 12 months later.

Of 75 phase 1 interventional studies under Alcoholism, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 6, 2024
StartEst.
Jul 1, 2025
Primary completionEst.
Jul 1, 2026
CompletionEst.
Sep 1, 2029
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06719908
Lead sponsor
Afasci Inc
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Jul 1, 2025 (estimated)
Primary completion
Jul 1, 2026 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Dec 6, 2024

Study contacts

Simon Xie, MD
Contact
simonxie@afasci.com
650-995-7320

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AFA-281

Start the discussion